CLINICAL_TRIALS ClinicalTrials.gov record update

A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03153462
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:29.399767+00:00
Published At: 2023-11-08T00:00:00+00:00
Record Updated At: 2023-11-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Relapsed/Refractory Diffuse Large B Cell Lymphoma", "Relapsed/Refractory Primary Mediastinal B Cell Lymphoma", "Relapsed/Refractory Transformed Follicular Lymphoma", "Relapsed/Refractory High-Grade B-Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-11-08"
protocolSection.identificationModule.nctId: "NCT03153462"
protocolSection.identificationModule.officialTitle: "A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma."
protocolSection.statusModule.overallStatus: "APPROVED_FOR_MARKETING"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.